CNBC's Pauline Choi reports on the spreading of pro-democracy protests in Hong Kong.
The FM traders share what stocks investors should be buying to protect their portfolio.
Dr. Joseph Kim, Inovio Pharmaceuticals CEO, discusses the production and fermentation technology of Inovio's Ebola vaccine.
CNBC's Kate Rogers reports the U.S. Ebola patient traveled part of his trip on United Airlines.
Mark Mahaney, RBC Capital Markets, analyzes Internet names going into the fourth quarter.
Discussing how Ebola impacts airlines and travel, with Jamie Baker, JPMorgan senior airline analyst.
CNBC's Patti Domm discusses how stocks stumbled into October after Wednesday's big losses.
"Shark Tank" investor Kevin O'Leary and CNBC's Rick Santelli discuss chaos surrounding Bill Gross' departure from Pimco.
Dissecting today's tape, with CNBC contributor Josh Brown; Nathan Bachrach, Simply Money Advisors: and CNBC's Dominic Chu.
CNBC's Bertha Coombs discusses the day's activity in the commodities markets. Traders say fundamentals are likely to continue to push down the price of oil. Gasoline futures rebounded, but are still down, she says.
David Nelson, Belpointe Asset Management, and Terry Dolan, Benjamin and Jerold Brokerage, dissect the day of trading.
CNBC's Dominic Chu explores possible market volatility for the month of October.
Rick Rieder, BlackRock, discusses what's behind today's selloff and if BlackRock is benefiting from Pimco outflows.
Discussing how to play current market volatility and the situation in Honk Kong, with CNBC contributor Jack Bouroudjian; Keith Fitz-Gerald Money Map Press; Jennifer Vail, U.S. Bank Wealth Management; and CNBC's Rick Santelli
Discussing fears of Ebola, the situation in Hong Kong and the best cybersecurity stocks, with Herjavec Group founder and Shark Tank host, Robert Herjavec.
Discussing fear in the market and the confluence of events that contribute to today's market decline, with Art Cashin, UBS director of floor operations, and Warren Meyers of Illustro Trading.
CNBC's Courtney Reagan looks at what small cap and technology names are driving down the Russell 2000.
Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.
Discussing headwinds facing the U.S. market amid a growth slowdown in the emerging world, with Jim McCaughan, Principal Global Investors CEO.
CNBC's Steve Liesman digs into weak economic data that is contributing to the market's decline.